Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: A substudy of the BICOMBO trial

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 711-718

  Curran, Adrian ^a   Martinez, Esteban ^b   Podzamczer, Daniel ^c   Lonca, Montserrat ^b   Barragan, Patricia ^c   Crespo, Manuel ^a   Falco, Vicenç ^a   Vidal Sicart, Sergio ^b   Imaz, Arkaitz ^c   Martinez, Maria ^b   Gatell, Jose Maria ^b   Ribera, Esteban ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; BONE DENSITY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADENINE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; BONE DENSITY; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DNA, MITOCHONDRIAL; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 84861710765     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2081     Document Type: Article

References (34)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (Updated 10 January 2001. Accessed 16 March 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
2. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. (Updated January 2001. Accessed 16 March 2011.) Available from http://www.gesida.seimc.org/index.asp
3. European AIDS Clinical Society Guidelines. Clinical management and treatment of HIV infected adults in Europe. Version 5.3. (Updated November 2009. Accessed 16 March 2011.) Available from http://www.eacs.eu/guide/index.htm
4. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-1960.
5. Parienti JJ, Bangsberg D, Verdon R, et al. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48:484-488.
6. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-723. (Pubitemid 34157656)
7. Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women. Clin Infect Dis 2005; 40:1837-1845. (Pubitemid 40799956)
8. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51:591-599.
9. Curran A, Ribera E. From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opin Drug Saf 2011; 10:389-406.
10. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
11. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260. (Pubitemid 43113030)
12. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147. (Pubitemid 46292215)
13. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263-270. (Pubitemid 38113036)
14. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215. (Pubitemid 34755281)
15. Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12:407-415. (Pubitemid 46787986)
16. Ribera E, Paradiñeiro JC, Curran A, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9:407-417.
17. Ribera E, Martínez E, Clotet B, et al. 72 Week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs Continuing on AZT/3TC. Final results of the RECOMB trial. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract CDB091.
18. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/ emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009; 51:562-568.
19. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050. (Pubitemid 44611057)
20. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601.
21. Bonnet E, Delpierre C, Sommet A, et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 2005; 8:287-292. (Pubitemid 41112844)
22. Degris E, Delpierre C, Sommet A, et al. Longitudinal study of body composition of 101 HIV men with lipodystrophy: dual-energy X-ray criteria for lipodystrophy evolution. J Clin Densitom 2010; 13:237-244.
23. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS ONE 2009; 4:e7038.
24. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a Substudy of ACTG A5202: a prospective, randomized, partially blinded Phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco CA, USA. Abstract 106LB.
25. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavirlamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-972.
26. van der Valk M, Casula M, Weverlingz GJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther 2004; 9:385-393. (Pubitemid 38878754)
27. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23. (Pubitemid 40111014)
28. Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51:290-297.
29. Martínez E, Larrousse M, Podzamczer D, et al. Objective amount of limb fat in HIV-infected subjects with subjective diagnosis of lipoatrophy. HIV Med 2009; 10:257-261.
30. Côté HC, Brumme Zl, Craib KJ, et al. Changes In Mitochondrial DNA as a Marker Of Nucleoside Toxicity In HIV-Infected Patients. N Engl J Med 2002; 346:811-820.
31. Hoy JF, Gahan ME, Carr A, et al. Changes in Mitochondrial DNA in Peripheral Blood Mononuclear Cells from HIV-Infected Patients with Lipoatrophy Randomized to Receive Abacavir. J Infect Dis 2004; 190:688-692. (Pubitemid 39049996)
32. Ananworanich J, Nuesch R, Côté HC, et al. Changes in metabolic toxicity after switching from stavudine/ didanosine to tenofovir/lamivudine -a Staccato trial substudy. J Antimicrob Chemother 2008; 61:1340-1343. (Pubitemid 351753605)
33. Maagaard A, Holberg-Petersen M, Kollberg G, et al. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11:601-608.
34. Madruga JR, Cassetti I, Suleiman JM, et al. The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1-Infected Patients: Three-Year Follow-up After Switching Therapy. HIV Clin Trials 2007; 8:381-390. (Pubitemid 350305212)